Omega-3 (EPA/DHA) for ADHD
Long-chain polyunsaturated fatty acids from fish or algal oil that are incorporated into cell membranes and reduce pro-inflammatory eicosanoid production; linked to cardiovascular, joint, and neurological benefits.
Omega-3 (EPA/DHA) for ADHD
5 of 7 results reported a benefit, from 3 published studies.
3 studies, including a review of trials · the chart counts everything measured
- 5 reported a benefit
- 2 no clear benefit
Colour keyReported a benefitNo clear benefitUnclearPossible harmAmber is for highlights, such as where the most research is. It never means a result was good.
- ADHD symptomsNo clear differencenegligible standardised effect1 review of trials2 of 3 results reported a benefit2023 study ↗
- Impulsive actionsNo clear benefit found1 randomised trial2022 study ↗
- Impulsive thinkingReported a benefit1 randomised trial2022 study ↗
- Not planning aheadReported a benefit1 randomised trial2022 study ↗
- Overall impulsivenessReported a benefit1 randomised trial2022 study ↗
These are the figures the studies reported, not a prediction for any one person. Where several studies measured the same thing in the same unit, we show a simple average and say so. Every result is listed below.
See every resultThe connection
Attention-deficit/hyperactivity disorder: persistent inattention, hyperactivity or impulsivity that disrupts daily life.
Also known as: Fish Oil, Krill Oil, EPA, DHA
Omega-3 (EPA/DHA) × ADHD: at a glance
Every published result for this pair, extracted and audited.
These charts count reported findings from published studies, grouped by reported benefit and study design. Study design is not a certainty grade.
Omega-3 (EPA/DHA) / ADHD: reported findings; one study may contribute several findings.
What the evidence shows
What this means: Counts describe research quantity, not treatment effectiveness or certainty.
| Category | Findings (count) |
|---|---|
| No benefit | 2 |
| Benefit | 5 |
Study designs behind these findings
What this means: Counts describe research quantity, not treatment effectiveness or certainty.
| Category | Findings (count) |
|---|---|
| Meta-analysis | 3 |
| Randomised trial | 4 |
- Studies
- 3
| Study | Outcome | Reported result | Uncertainty (as reported) | Study duration |
|---|---|---|---|---|
| Omega-3 Polyunsaturated Fatty Acids for Core Symptoms of Attention-Deficit/Hyperactivity Disorder: A Meta-Analysis of Randomized Controlled Trials. (PMID 37656283) | ADHD core symptoms (overall) | SMD: -0.16 | 95% CI, -0.34 to 0.01; P = .07 | Not reported |
| Omega-3 Polyunsaturated Fatty Acids for Core Symptoms of Attention-Deficit/Hyperactivity Disorder: A Meta-Analysis of Randomized Controlled Trials. (PMID 37656283) | ADHD core symptoms (treatment duration ≥ 4 months) | SMD: -0.35 | 95% CI,-0.61 to -0.09; P = .007 | at least 4 months |
| Omega-3 fatty acid supplementation for the treatment of children with attention-deficit/hyperactivity disorder symptomatology: systematic review and meta-analysis. (PMID 21961774) | ADHD severity (standardized mean difference in rating scales) | Not reported | Not reported | Not reported |
| Impulsiveness in children with attention-deficit/hyperactivity disorder after an 8-week intervention with the Mediterranean diet and/or omega-3 fatty acids: a randomised clinical trial. (PMID 34656505) | Total BIS-11c score | Not reported | P = .049 | 8 weeks |
| Impulsiveness in children with attention-deficit/hyperactivity disorder after an 8-week intervention with the Mediterranean diet and/or omega-3 fatty acids: a randomised clinical trial. (PMID 34656505) | Total cognitive score | Not reported | Not reported | 8 weeks |
| Impulsiveness in children with attention-deficit/hyperactivity disorder after an 8-week intervention with the Mediterranean diet and/or omega-3 fatty acids: a randomised clinical trial. (PMID 34656505) | Total motor score | Not reported | Not reported | 8 weeks |
| Impulsiveness in children with attention-deficit/hyperactivity disorder after an 8-week intervention with the Mediterranean diet and/or omega-3 fatty acids: a randomised clinical trial. (PMID 34656505) | Total nonplanning scores | Not reported | Not reported | 8 weeks |
Study results, as reported by the publications
Every measured outcome, one row per finding - numbers exactly as reported. Units are preserved where supplied; missing units are not inferred.
| Study and type | Reported sample and duration | Outcome measured | Reported result | What studies found |
|---|---|---|---|---|
| PMID 37656283 2023 Meta-analysis | Sample (as reported): 1,789Duration: Not reported | ADHD core symptoms (overall) | SMD: -0.16 (95% CI, -0.34 to 0.01; P = .07) | No benefit |
| PMID 37656283 2023 Meta-analysis | Sample (as reported): Not reportedDuration: at least 4 months | ADHD core symptoms (treatment duration ≥ 4 months) | SMD: -0.35 (95% CI,-0.61 to -0.09; P = .007) | Benefit |
| PMID 21961774 2011 Meta-analysis | Sample (as reported): 699Duration: Not reported | ADHD severity (standardized mean difference in rating scales) | Not reported | Benefit |
| PMID 34656505 2022 Randomised trial | Sample (as reported): 60Duration: 8 weeks | Total BIS-11c score | Not reported (P = .049) | Benefit |
| PMID 34656505 2022 Randomised trial | Sample (as reported): 60Duration: 8 weeks | Total cognitive score | Not reported | Benefit |
| PMID 34656505 2022 Randomised trial | Sample (as reported): 60Duration: 8 weeks | Total motor score | Not reported | No benefit |
| PMID 34656505 2022 Randomised trial | Sample (as reported): 60Duration: 8 weeks | Total nonplanning scores | Not reported | Benefit |
Omega-3 (EPA/DHA) × ADHD: the evidence base
Hand-selected PubMed studies, linked to the originals.
Ordered by strength of evidence, then result direction.
01Role of the EPA: DHA dosing ratio in omega-3 supplements on blood fatty acid profiles and inflammation: a systematic review and meta-analysisKhabir Z, et al. · Critical reviews in food science and nutrition · 2026PMID 41568426 ↗02Efficiency of Different Supplements in Alleviating Symptoms of ADHD with or Without the Use of Stimulants: A Systematic ReviewAl Shahab S, et al. · Nutrients · 2025PMID 40362791 ↗03Comparative Effectiveness of Nutritional Supplements in the Treatment of Knee Osteoarthritis: A Network Meta-AnalysisZhang Y, et al. · Nutrients · 2025PMID 40806131 ↗04A systematic review and dose response meta analysis of Omega 3 supplementation on cognitive functionShahinfar H, et al. · Scientific reports · 2025PMID 40836005 ↗05The effect of two anti-inflammatory dietary components, omega-3 and resveratrol, on endometriosisSienko A, et al. · Ginekologia polska · 2024PMID 37768015 ↗06A Systemic Review on Nutraceutical Supplements used in the Management of OsteoarthritisNooreen Z, et al. · Recent advances in food, nutrition & agriculture · 2024PMID 38258782 ↗Community experiences
Contributors volunteered; this does not establish treatment effectiveness or population incidence.
Reported changes
No publishable community breakdown is available. This does not establish that no reports exist.